New PET tracer could make pituitary tumor imaging more accessible
NCT ID NCT06584123
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study at the University of Cambridge is testing whether a new PET scan tracer called FET can locate pituitary tumors as well as the standard tracer, methionine. The study involves 20 adults with suspected pituitary adenomas who have already had a methionine PET scan. If FET works similarly, it could be easier to produce and distribute, potentially expanding access to this type of imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-fluoro-ethyl-tyrosine (FET) PET tracer
What this could lead to
If FET works as well as the current tracer, it could make advanced pituitary tumor imaging more widely available, since FET is easier to produce and distribute.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is also testing a diagnostic tool, not a treatment, so it won't directly improve health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITUITARY ADENOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals
RECRUITINGCambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact